J. Clin. Med. 2014, 3(2), 521-536; doi:10.3390/jcm3020521

Prevention of Bone Metastases in Breast Cancer Patients. Therapeutic Perspectives

* email and email
Received: 2 February 2014; in revised form: 3 March 2014 / Accepted: 14 March 2014 / Published: 9 May 2014
(This article belongs to the Special Issue Prevention and Treatment of Bone Metastases from Breast Cancer)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: One in four breast cancer patients is at risk of developing bone metastases in her life time. The early prevention of bone metastases is a crucial challenge. It has been suggested that the use of zoledronic acid (ZOL) in the adjuvant setting may reduce the persistence of disseminated tumor cells and thereby might improve outcome, specifically in a population of patients with a low estrogen microenvironment. More recently, the results of a large meta-analysis from 41 randomized trials comparing a bisphosphonate (BP) to placebo or to an open control have been presented at the 2013 San Antonio Breast Cancer Meeting. Data on 17,016 patients confirm that adjuvant BPs, irrespective of the type of treatment or the treatment schedule and formulation (oral or intra-venously (IV)), significantly reduced bone recurrences and improved breast cancer survival in postmenopausal women. No advantage was seen in premenopausal women. BPs are soon likely to become integrated into standard practice. Published data on the mechanisms involved in tumor cell seeding from the primary site, in homing to bone tissues and in the reactivation of dormant tumor cells will be reviewed; these might offer new ideas for innovative combination strategies.
Keywords: breast cancer; bone metastasis; adjuvant treatment; neoadjuvant treatment; bisphosphonates; zoledronic acid; denosumab; osteonecrosis of the jaw
PDF Full-text Download PDF Full-Text [237 KB, uploaded 9 May 2014 10:32 CEST]

Export to BibTeX |

MDPI and ACS Style

Beuzeboc, P.; Scholl, S. Prevention of Bone Metastases in Breast Cancer Patients. Therapeutic Perspectives. J. Clin. Med. 2014, 3, 521-536.

AMA Style

Beuzeboc P, Scholl S. Prevention of Bone Metastases in Breast Cancer Patients. Therapeutic Perspectives. Journal of Clinical Medicine. 2014; 3(2):521-536.

Chicago/Turabian Style

Beuzeboc, Philippe; Scholl, Suzy. 2014. "Prevention of Bone Metastases in Breast Cancer Patients. Therapeutic Perspectives." J. Clin. Med. 3, no. 2: 521-536.

J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert